Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles (original) (raw)
Tsukasa Baba2016, Gynecologic Oncology
visibility
…
description
8 pages
link
1 file
Related papers
Analysis of 300 Clinical Cases of Ovarian Cancer
International Journal of Research Publication and Reviews, 2024
Targeting dormant ovarian cancer cells in vitro and in an in vivo model of platinum resistance
2019
Scientific Reports, 2021
Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer
PLoS ONE, 2009
The association of taxane resistance genes with the clinical course of ovarian carcinoma
Genomics, 2013
Asian Pacific Journal of Cancer Prevention, 2023
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies
Gynecologic Oncology, 2016
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Cell, 2016
Gynecologic Oncology
Biomarkers capable to predict response to platinum and taxane combination treatment in ovarian tumors were identified. • Proteins including NCOR2, TFE3, AKIP1 and AKIRIN2 were among the most significant genes validated in an independent cohort. • The integrated database with available treatment and response data can be mined to validate new biomarker candidates.
Analysis of Gene Expression in Early-Stage Ovarian Cancer
Clinical Cancer Research, 2008
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Related papers
Explaining Ovarian Cancer Gene Expression Profiles with Fuzzy Rules and Genetic Algorithms
Electronics, 2021
Proteomic analysis of progressive factors in uterine cervical cancer
PROTEOMICS, 2005
Role of apoptotic regulators in human epithelial ovarian cancer
Cancer Biology & Therapy, 2007
Assessment of pathogenic variation in gynecologic cancer genes in a national cohort
Scientific Reports, 2023
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
Frontiers in Immunology, 2023
Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
BMC Cancer, 2015
Integrated genomic analyses of ovarian carcinoma
Nature, 2011
An In Silico Study to Explore the Role of EGFR in Ovarian Cancer
Pharmacognosy Journal
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer
Genome Research, 2010
Journal of Turkish Society of Obstetric and Gynecology, 2018
Evaluation of taxane effects in pancreatic cancer models
HPB, 2018
Recent developments in cancer research: Expectations for a new remedy
Annals of Gastroenterological Surgery
Gynecologic Oncology, 2005
Data from Validation of a Radiosensitivity Molecular Signature in Breast Cancer
2023
The role of selected molecular factors in ovarian cancer metastasis
Ginekologia Polska
Predictors of residual disease after debulking surgery in advanced stage ovarian cancer
Frontiers in Oncology, 2023
PARP inhibitors in ovarian cancer
Cancer Treatment Reviews, 2018
The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer
PLoS ONE, 2013
Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?
Cancer, 2015
Early detection of ovarian cancer using group biomarkers
Amy P N Skubitz, Alain Tchagang
Molecular Cancer Therapeutics, 2008
2007
American Journal of Obstetrics and Gynecology, 2006
Inhibitors that target protein kinases for the treatment of ovarian carcinoma
American Journal of Obstetrics and Gynecology, 2003
Gene expression profile in breast cancer comprising predictive markers for metastatic risk
Genetics and Molecular Research, 2015
BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival
Clinical Cancer Research, 2011
Related topics
OncologyOvarian CancerMedicineEpithelial-Mesenchymal TransitionTranscriptomeInternal MedicineGynecologic OncologyPaclitaxelCisplatinmicroRNAsRegimenAntineoplastic AgentsCarboplatinPaediatrics and reproductive med...Ovarian Neoplasms